Avian Influenza Virus Type A N3 subtype N3/NA3 antibody and antigen (recombinant protein)
Diagnostic anti-Avian Influenza Virus Type A N3 subtype N3/NA3 antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Avian/Bird/Poultry disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P216-Tg001-Ag01 | Recombinant Avian Influenza Virus Type A N3 subtype N3/NA3 protein | $3090.00 |
GMP-VT-P216-Tg001-Ab01 | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P216-Tg001-Ab02 | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P216-Tg001-Ab03 | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 human monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P216-Tg001-Ab04 | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P216-Tg001-Ag01 |
Product Name | Recombinant Avian Influenza Virus Type A N3 subtype N3/NA3 protein |
Pathogen | Avian Influenza Virus Type A N3 subtype |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus Type A N3 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Tag | His | Product description | Recombinant Avian Influenza Virus Type A N3 subtype N3/NA3 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P216-Tg001-Ab01,GMP-VT-P216-Tg001-Ab02 |
Pathogen | Avian Influenza Virus Type A N3 subtype |
Product Name | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Avian Influenza Virus Type A N3 subtype N3/NA3 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A N3 subtype antibodies in Avian Influenza Virus Type A N3 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Product description | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A N3 subtype antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P216-Tg001-Ab03,GMP-VT-P216-Tg001-Ab04 |
Pathogen | Avian Influenza Virus Type A N3 subtype |
Product Name | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Avian Influenza Virus Type A N3 subtype N3/NA3 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A N3 subtype antibodies in Avian Influenza Virus Type A N3 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza. |
Product description | Anti-Avian Influenza Virus Type A N3 subtype N3/NA3 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Pathogen Information
Avian Influenza Virus Type A N3 subtype, referred to as bird flu, is a highly contagious and pathogenic virus that belongs to the family Orthomyxoviridae. The virus has a segmented genome composed of eight negative-sense RNA molecules and can cause severe respiratory illness in humans and many bird species, leading to significant economic harm in the poultry industry.
Avian Influenza Virus Type A N3 subtype has two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which are involved in the viral life cycle. HA plays a crucial role in attaching to the host cell receptor, while NA cleaves sialic acid residues on the cell surface to facilitate the release of progeny virions. The HA protein is highly polymorphic, allowing the virus to evade immune responses through antigenic drift and shift.
In birds, Avian Influenza Virus Type A N3 subtype, along with other influenza virus subtypes, can cause disease ranging from subclinical infections to severe health complications and death. Symptoms include respiratory signs, decreased egg production, and increased mortality. The virus is primarily transmitted by direct or indirect contact with infected birds or their feces, as well as from contaminated feed, water, and equipment.
Despite the virus's natural host being birds, Avian Influenza Virus Type A N3 subtype has crossed species barriers and caused sporadic infections in humans, raising concerns over its pandemic potential. Human infection has occurred through close contact with infected poultry or contaminated environments but cannot be transmitted through properly cooked poultry products. In human cases, the symptoms of Avian Influenza Virus Type A N3 subtype can range from mild flu-like symptoms to severe respiratory illness that can be fatal. The elderly and those with pre-existing medical conditions are particularly susceptible to severe disease and death.
Timely and sensitive diagnostic methods are necessary for the rapid detection of Avian Influenza Virus Type A N3 subtype. Currently, nucleic acid-based tests, such as PCR and rRT-PCR, are widely used for detecting the virus in clinical samples. The tests amplify specific regions of the viral genome, including HA and NA genes, to provide accurate and definitive diagnosis. Serologic tests have also been developed to detect antibodies produced in response to the virus during acute or convalescent stages of infection.
Efforts to control and prevent the spread of Avian Influenza Virus Type A N3 subtype include strict biosecurity measures on commercial poultry farms, vaccination programs, and culling infected birds. The World Health Organization (WHO) and the Food and Agriculture Organization of the United Nations (FAO) recommend regular surveillance of the virus in both avian and human populations to detect potential outbreaks and minimize risks to public health.
In conclusion, Avian Influenza Virus Type A N3 subtype is a significant pathogen that poses a threat to animal and human health. Understanding its molecular biology, transmission, and pathogenesis is essential for the development of effective control strategies. Heightened awareness, timely diagnosis, and appropriate public health measures remain key considerations to ensure the prevention and control of this potentially devastating disease.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.